Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 4
Submit an article Journal homepage
337
Views
13
CrossRef citations to date
0
Altmetric
Letters to the Editor

CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis

Amir T. FathiMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USACorrespondence[email protected]
,
Frederic I. PrefferMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
,
Hossein SadrzadehMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
,
Karen K. BallenMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
,
Philip C. AmreinMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
,
Eyal C. AttarMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
,
Steven L. McAfeeMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
,
Laura DillonMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
,
Yi-Bin ChenMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
&
Robert P. HasserjianMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
 show all
Pages 860-863 | Received 27 Jul 2012, Accepted 06 Sep 2012, Published online: 28 Sep 2012

References

  • Estey E. AML in older patients: are we making progress? Bailliere's Best Pract Clin Haematol 2009;22:529–536.
  • Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051–1062.
  • Stein H, Delsol G, Pileri SA, . Classical Hodgkin lymphoma: introduction. In: Swerdlow SH, Campo E, Harris NL, ., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp 326–329.
  • Durkop H, Latza U, Hummel M, . Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992;68:421–427.
  • Falini B, Pileri S, Pizzolo G, . CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;85:1–14.
  • Chen R, Gopal AK, Smith SE, . Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Blood 2010;116(Suppl. 1): Abstract 283.
  • Younes A, Bartlett NL, Leonard JP, . Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812–1821.
  • Shustov AR, Advani R, Brice P, . Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2010;116(Suppl. 1): Abstract 961.
  • Ezawa H, Harigaya K, Ishii G, . 12-O-tetradecanoylphorbol-13-acetate (TPA) downregulates expression of CD30 in erythroleukemia cell line K562. Hematol Oncol 1997;15:151–161.
  • Fickers M, Theunissen P. Granulocytic sarcoma with expression of CD30. J Clin Pathol 1996;49:762–763.
  • Horie R, Gattei V, Ito K, . Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms. Am J Pathol 1999;155:2029–2041.
  • Gattei V, Degan M, Gloghini A, . CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997;89:2048–2059.
  • Horie R, Ito K, Tatewaki M, . A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages. Blood 1996;88:2422–2432.
  • Kiyoi H, Naoe T, Nakano Y, . Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999;93:3074–3080.
  • Kottaridis PD, Gale RE, Frew ME, . The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752–1759.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.